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Abstract
Deletion or epigenetic inactivation of the tumor
suppressor gene p16
INK4A/CDKN2 (p16) has been
observed in multiple human tumors. We assayed hybrid
cell lines between human diploid fibroblasts and
fibrosarcoma cells for p16 allelic status and expression
and found that p16 was expressed in the parental
diploid fibroblast cell lines used, whereas the parental
fibrosarcoma cell line HT1080.6TG exhibited
homozygous deletion of p16. Most immortalized hybrid
cell lines derived from these parent cell lines, whether
tumorigenic or nontumorigenic, exhibited loss of
fibroblast-derived p16 alleles. All p16-negative hybrid
cell lines also exhibited deletion of p15
INK4B (p15).
Hybrid cell lines yielded tumors upon s.c. injection into
athymic nude mice regardless of p16/p15 status.
Tumors derived from six p16/p15-positive hybrid cells,
however, revealed deletions of both p16 and p15. When
human diploid fibroblasts were fused with A388.6TG
squamous cell carcinoma cells, which exhibit aberrant
methylation of p16, the resulting hybrids again
exhibited deletion of the unmethylated fibroblast-
derived p16 alleles. Transfection of both HT1080.6TG
and A388.6TG cells with wild-type p16 expression
vector resulted in decreased clonogenicity in culture.
Although the determinants directing genetic versus
epigenetic inactivation of p16 and p15 remain unclear,
these results demonstrate that p16-mediated growth
suppression could be abrogated by either mechanism
in somatic cell hybrids.
Introduction
Inactivation of the cyclin-dependent kinase 4 inhibitor-
encoding genes p16
INK4A/CDKN2 (p16) and p15
INK4B (p15)i n
many tumors strongly suggests a role for these genes in the
regulatory programs disturbed during cellular transforma-
tion. Although homozygous deletions involving chromosomal
segment 9p21 in melanoma cell lines led to the initial iden-
tification of these genes (1, 2), deletions involving one or both
loci have been described in multiple tumors, including can-
cers of the head and neck (3, 4), prostate, bladder, and lung
(3); tumors of the central nervous system (5); and acute
leukemias (6). Interestingly, although germ-line mutations of
p16 were identified in families exhibiting a predisposition to
melanoma (7), point mutations in the p16 gene in sporadic
tumors appear to be relatively uncommon (8–10). More re-
cently, epigenetic transcriptional repression, characterized
by aberrant methylation of the CpG-rich promoter, has been
shown to inactivate both p16 (11–15) and p15 (16) in a
variety of tumors. Similar aberrant epigenetic silencing has
also been shown to inactivate the retinoblastoma (17), von
Hippel-Lindau (18), and human mutL homologue (19) tumor
suppressor genes in nonfamilial tumors.
Somatic cell hybrids constructed by fusing neoplastic and
nonneoplastic cells have proven to be important tools for
testing the relevance of putative tumor-inducing inactivating
mutations observed in primary tumors and cell lines. The
recapitulation in the hybrid cells of these deletions and mu-
tations on alleles derived from the nonneoplastic parental cell
line, associated with the acquisition of neoplastic pheno-
types, provides functional evidence for tumor suppressor
activity encoded by the gene or within the chromosomal
region in question (20, 21). We assessed the p16 and p15
status of somatic cell hybrids constructed between nonim-
mortalized human fibroblasts and either human fibrosarcoma
cells, in which p16 and p15 are deleted, or human squamous
cell carcinoma cells, in which p16 exhibits epigenetic inac-
tivation. The results support the genetic data, indicating a
growth suppressor role for p16 and p15. The data under-
score the applicability of somatic hybridization experiments
to the study of epigenetic mechanisms in tumorigenesis and
demonstrate the potential role of epigenetic processes in
gene inactivation events associated with neoplastic progres-
sion in somatic cell hybrids.
Results
Deletion of p16 and p15 in HT1080.6TG Fibrosarcoma
Cells and in Human Diploid Fibroblast 3 Fibrosarcoma
Hybrid Cells. To assess the status of p16 in parental and
hybrid cell lines, we used multiplex PCR assays in which a
p16 exon 2 fragment was coamplified from genomic DNA
with a c-myc fragment to control for integrity of the DNA
sample. Analyses of the parental cell lines GM02291 and
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SFTH300TR1 (22) are shown in Fig. 1A. A band correspond-
ing to the c-myc amplification product was detected in PCRs
from all four cell lines. A band corresponding to the p16
amplification products was also observed in the GM02291
fibroblast reaction. No p16-specific product was apparent,
however, in PCRs using genomic DNA from HT1080.6TG
fibrosarcoma cells or from either the nontumorigenic
SFTH300 or the tumorigenic SFTH300TR1 hybrid cell lines
(Fig. 1A). The status of p15 was also assessed using primers
generating a fragment encompassing p15 exon 1. Again, a
p15-specific amplification product was observed only in the
GM02291 reaction (Fig. 1B). Thus, the parental HT1080.6TG
fibrosarcoma cells showed homozygous deletion of p16 and
p15. In addition, the deletion of fibroblast-derived alleles of
p16 and p15 in both the nontumorigenic and tumorigenic
hybrid cell lines demonstrates that inactivation of these
genes accompanied events leading to immortalization and
preceded tumorigenic transformation in this system.
Deletion of p16 in K894 Hybrid Cell Lines and in K894-
derived Tumors. To test the hypothesis that deletion/inac-
tivation of p16 is a step in neoplastic transformation of fibro-
blast 3 fibrosarcoma hybrids, we analyzed a second hybrid
series comprising the parental cell lines BBT and 1080NR.4
as well as 50 BBT 3 1080NR.4 hybrid cell lines designated
K894 (Table 1). Multiplex PCR for p16/c-myc of BBT fibro-
blast-derived genomic DNA revealed the expected p16-spe-
cific product (Fig. 2A). Analysis of the K894 hybrid cell lines
at passage 2, however, revealed the p16 band in only 19 of
50 cell lines (data not shown). Thus, as was observed with
the SFTH hybrid cells, the majority of K894 hybrid cell lines
exhibited early deletion of fibroblast-derived p16 alleles.
To determine whether tumorigenicity correlated with p16/
p15 status in the hybrid cell lines, cells from six p16-positive
and six p16-negative K894 cell lines were injected s.c. into
the flank tissues of athymic nude mice. Tumors developed in
all evaluable animals injected with parental 1080NR.4 fibro-
sarcoma cells or any of the 12 hybrid cell lines, whereas no
tumors developed in mice injected with parental BBT fibro-
blasts (Table 2). Although tumors derived from hybrid line
K894.19 developed more slowly than others, no general
difference in tumor latency was noted between p16-positive
and p16-negative cell lines. Tumors derived from the six
p16-positive hybrid cell lines (Fig. 2A) were then assayed for
p16 status. Of 12 independent tumors tested, p16 was un-
detectable by PCR analysis of 11 samples (Fig. 2B). Although
a faint p16-specific band was detectable in PCR products
from genomic DNA of K894.12T1 tumor cells (Fig. 2B), no
p16-specific band was detectable by Southern blot analysis
of genomic DNA from these cells (data not shown). The total
or near total loss of p16 in all tumors derived from p16-
positive hybrid cell lines confirmed that growth of these cell
lines, either in culture or as tumor xenografts, entailed a
selection against p16 expression.
Deletion of p15 in K894 Hybrids and Hybrid-derived
Tumors. Because HT1080.6TG cells and the hybrid cell
lines SFTH300 and SFTH300TR1 exhibited loss of both p16
and p15, we asked whether p15 was also deleted in K894
hybrids and hybrid-derived tumors. PCR analysis of six p16-
positive hybrid cell lines revealed a p15-specific band (Fig.
3), whereas analysis of multiple p16-negative hybrid lines
revealed concordant loss of p15 (data not shown). When
tumors derived from p16/p15-positive hybrid cells were an-
alyzed for p15 status, all exhibited loss of p15 (Fig. 3), sug-
gesting that growth of the hybrid cell lines was also facilitated
by the deletion of p15.
Expression of p16 and p15 mRNAs in Fibroblasts and in
p16-/p15-positive Hybrid Cell Lines. To document expres-
sion of p16 or p15 mRNA in fibroblasts and in hybrid cell lines
that were p16-/p15-positive by genomic PCR, we used mul-
tiplex RT-PCR
4 assays. Such documentation was of partic-
ular significance with respect to p16 expression because
hybrid cell lines positive for p16 exon 2 by genomic PCR
could still harbor a deletion involving exon 1 and/or its ad-
jacent promoter (23, 24). Therefore, primers specific for p16
exon 1 and exon 3 sequences were combined with primers
specific for a portion of the GAPDH transcript to control for
RNA integrity in a multiplex RT-PCR assay. BBT parental
4 The abbreviations used are: RT-PCR, reverse transcription-PCR;
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; EMEM, Eagle’s
MEM; FBS, fetal bovine serum.
Fig. 1. Deletion of p16 and p15 in HT1080.6TG fibrosarcoma cells and
hybrid cell lines. Genomic DNA was amplified with primers specific for
c-myc and p16 [exon 2 (A)] or c-myc and p15 [exon 1 (B)].
28 p16/p15 Deletion in Human Somatic Cell Hybridsfibroblasts, 1080NR.4 parental fibrosarcoma cells, and three
K894 hybrid cell lines that were p16 positive by genomic
PCR were analyzed. A p16-specific RT-PCR product was
detected in all cell line samples except 1080NR.4 (Fig. 4A).
Similarly, the assay for p15 expression used primers span-
ning the p15 coding sequence in combination with GAPDH-
specific primers. Analysis once again revealed p15 expres-
sion only in the fibroblasts and the p15 genomic PCR-
positive hybrid cell lines (Fig. 4B). Therefore, these assays
confirmed p16 and p15 expression in those cell lines that
were positive by p16 or p15 genomic PCR.
Chromosome 9p Deletions in HT1080.6TG Cells and
K894 Hybrid-derived Tumors. To determine the extent of
the chromosome 9p deletion in HT1080.6TG cells and hy-
brid-derived tumors, PCR analysis using microsatellite mark-
ers was performed. As summarized in Table 3, the homozy-
gous 9p deletion in HT1080.6TG cells was bounded
proximally by the marker D9S171 and distally by D9S157.
Seven tumors derived from p16/p15-positive K894 hybrid
cell lines were then analyzed to map deletions of parental
fibroblast-derived chromosome 9 alleles. Because the pa-
rental HT1080.6TG cells and fibroblasts shared one common
allele at D9S197 and D9S269, we could not establish unam-
biguous deletion of both fibroblast-derived alleles at these
loci in the hybrid cell lines. Nevertheless retention of unique
fibroblast-derived alleles of these and other loci in two of the
seven hybrid cell lines confined the largest region of deletion
to that region bounded by D9S259 proximally and by
Table 1 Cell lines
Parental cell lines Hybrid cell lines Properties
GM02291 Human fibroblast, nonimmortalized
HT1080.6TG Human fibrosarcoma, immortalized, tumorigenic
SFTH300 Immortalized, nontumorigenic
SFTH300TR1 Immortalized, tumorigenic
BBT Human fibroblast, nonimmortalized
1080NR.4 Neomycin-resistant subclone of HT1080.6TG
K894 Immortalized
GM01429 Human fibroblast, nonimmortalized, p16 alleles unmethylated
388NR.4 Human squamous cell carcinoma, immortalized, tumorigenic, p16 alleles
methylated
Hy397 Immortalized
Fig. 2. Deletion of p16 in tumors derived from p16-positive hybrid cell
lines. A, genomic DNA from the parental fibroblast and fibrosarcoma cell
lines as well as six K894 hybrid cell lines was amplified with p16 (exon 2)
and c-myc primers. No DNA template was added to the control reaction.
B, p16 and c-myc genomic PCR products amplified from DNA of two
independent tumors derived from each hybrid cell line are shown.
Table 2 Tumorigenicity of K894 hybrid cell lines
Cell line p16 status
No. of tumors/
no. of mice
injected
Latency
(weeks)
a
Parental cell lines
BBT 1 0/2 NA
b
1080NR.4 2 5/5 2
Hybrid cell lines
K894.11 2 4/4 2
K894.12 1 2/4
c 4
K894.16 2 4/4 3
K894.18 1 4/4 3
K894.19 1 4/4 6
K894.22 2 4/4 3
K894.23 1 4/4 3
K894.32 2 4/4 3
K894.36 1 4/4 3
K894.39 2 4/4 3
K894.40 2 4/4 3
K894.42 1 4/4 3
a Average time until tumors measured 0.5 cm in largest dimension.
b NA, not applicable.
c Two mice died before tumors were identifiable.
Fig. 3. Deletion of p15 in tumors derived from p15-positive K894 hybrid
cell lines. Genomic DNA from the parental fibroblast and fibrosarcoma cell
lines as well as six K894 hybrid cell lines and two independent tumors
(designated T1 and T2) derived from each hybrid cell line was amplified
with primers for for p15 (exon 1) and c-myc.
29 Cell Growth & DifferentiationD9S157 distally (indicated by the dashed box in Table 3).
This deletion was similar in extent to the deletion in
HT1080.6TG cells. No other regions of fibroblast-derived
chromosome 9 were consistently deleted in the tumor cells.
Deletion of p16 in Human Squamous Cell Carcinoma 3
Human Fibroblast Hybrids. Epigenetic transcriptional re-
pression associated with aberrant promoter methylation and
chromatin condensation is an alternative mechanism of tu-
mor suppressor gene inactivation. Because deletion of p16
was observed exclusively in K894 hybrid cells, we extended
our analysis to somatic cell hybrids constructed from a pa-
rental cell line in which p16 was inactivated by epigenetic
repression rather than deletion. We made hybrids between
the human fibroblast cell line GM01429, which has normal,
unmethylated p16 alleles, and 388HR.4, a squamouscell car-
cinoma cell line that exhibits aberrant methylation of the p16
promoter (Table 1). Five hybrid cell lines, termed Hy397, were
derived from two cell fusion experiments, selecting for re-
tention of the GM01429-derived t(Xq;9p) chromosome by
culturing the hybrids in hypoxanthine, aminopterin, and thy-
midine medium. An informative MspI polymorphism in p16
exon 3 (10) permitted discrimination between parental p16
alleles in these hybrid cells. Although analysis of all Hy397
hybrid cell lines at passage 2 revealed both GM01429-de-
rived and 388HR.4-derived p16 alleles (data not shown),
repeat analysis at passage 20 (;50 population doublings)
revealed only 388HR.4-derived alleles (Fig. 5A). To verify
further that the hybrids originally contained at least one
GM01429-derived chromosome 9, we assessed the Hy397
hybrids for retention of some element of the fibroblast-
derived chromosome. Microsatellite analysis for chromo-
some 9 loci confirmed the retention of one GM01429-derived
allele at locus D9S273 (9p21-q21) in all Hy397 hybrid cell
lines at passage 20 (Fig. 5B). These data demonstrate that
passage in cell culture selected for the deletion but not the de
novo methylation of unmethylated GM01429-derived p16
alleles in Hy397 hybrid cells, whereas methylated 388NR.4-
derived alleles were retained.
Suppressed Clonogenicity in p16-transfected HT-
1080.6TG Cells and A388.6TG Cells. Because the genetic
and epigenetic changes demonstrated in these hybrid cell
lines and hybrid-derived tumors could potentially inactivate
genes other than p16 and p15, we asked directly whether
p16 expression conferred growth suppression in the parent
tumor cell lines. HT1080.6TG cells and A388.6TG cells were
transfected with pCDKN2AWT, an expression vector encod-
ing the wild-type p16 cDNA driven by a cytomegalovirus
promoter. For both tumor cell lines, transfection with the
wild-type p16-containing plasmid resulted in substantially
reduced clonogenicity in cell culture compared to transfec-
tion to the vector alone (Table 4). The magnitude of this
suppression, although less than total, was comparable to
that observed in previous studies (9, 25).
Discussion
The hybrid cell lines SFTH300 and SFTH300TR1 have been
used previously to analyze genetic and epigenetic events in
relationship to cellular immortalization, tumorigenicity in
athymic nude mice, and other neoplastic phenotypes (22, 26,
27). We recently demonstrated the deletion in immortalized,
tumorigenic SFTH300TR1 cells of chromosome 17 loci that
were retained in immortalized but nontumorigenic SFTH300
cells, suggesting a possible role for these genetic events in
tumorigenic transformation rather than immortalization (26).
Here, in contrast, p16 and p15, deleted in the parental
HT1080.6TG cells, were also deleted in nontumorigenic
SFTH300 cells, demonstrating that p16/p15 deletion was not
sufficient to establish tumorigenicity in these hybrid cells and
suggesting that the process of immortalization in culture
selected against cells expressing these genes.
Data from a second series of hybrid cell lines supported
these results. Early deletion (passage 2) of fibroblast-derived
p16 and p15 was observed in the majority of K894 hybrid cell
lines. In tumorigenicity assays, tumors developed rapidly in
nude mice injected with K894 hybrid cell lines, regardless of
p16/15 status. Importantly, however, tumors derived from
p16/p15-positive hybrids exhibited total or near total loss of
fibroblast-derived p16 and p15. As assessed by the retention
or loss chromosome 9 loci in the tumors (Table 3), the gene(s)
accounting for the tumor suppressive effect inferred by the
deletion of fibroblast-derived alleles map to the region 9p21-
p22, and p16 and p15 remain the best candidates.
Although the data from the K894 hybrids do not demon-
strate an exclusive association of p16/p15 inactivation with
immortalization versus tumorigenicity, the early deletion of
Fig. 4. Expression of p16 and p15 in genomic PCR-positive cell lines.
RNA from parental and hybrid cell lines was reverse transcribed, and the
resultant cDNA was amplified using primers for GAPDH and (A) p16
(exons 1a and 3) or (B) p15 (exons 1 and 2).
30 p16/p15 Deletion in Human Somatic Cell Hybridsp16 and p15 in more than half of the cell lines indicatesthat
expression of these genes probably suppressed growth of
the hybrid cells in culture. The deletion of fibroblast-derived
p16 alleles in Hy397 hybrids following extended passage in
culture suggests further that loss of p16-facilitated growth in
cell culture. Because the assay for p16 and p15 status was
PCR based, the deletion of p16 and p15 observed in tumors
derived from hybrid cell lines positive for both genes may
reflect heterogeneity of the original hybrid cell population.
Indeed, the short latency periods associated with tumor for-
mation suggest selective expansion of a preexisting p16-/
p15-negative cell population. The reduced clonogenicity ob-
served in the p16-transfected parental HT1080.6TG and
A388.6TG tumor cell lines confirms the growth-suppressive
effect of p16 inferred by the deletion of the gene during
growth of hybrid cells. Our results support previous data for
p16- (9, 25, 28) or p15- (29) mediated growth suppression.
Serrano, et al. (30) suggested a role for p16 activity in
senescence of fibroblasts based on the enhanced clono-
genic potential and lack of senescent growth delay exhibited
by p16 null (2/2) mouse embryo fibroblasts. Furthermore,
they noted an increased frequency of fibrosarcoma devel-
opment, both spontaneously and following UV radiation or
chemical mutagenesis, in p16 nullizygous mice compared to
controls. The specific role of p16 inactivation in the evolution
of these transformation events has been called into question
by recent experiments using mice that were nullizygous for
p19
ARF, the product of an alternate reading frame encoded at
the INK4A locus, but expressed p16. Embryo fibroblasts
from these mice also exhibit increased immortalization fre-
quency, and the mice show an increased susceptibility to
spontaneous and carcinogen-induced tumors, including fi-
brosarcomas (31). Our results support a role for p16 and/or
p15 inactivation in fibroblastic tumors or tumors of primitive
mesenchymal origin, in agreement with recent data (32).
Because the deletions we observed encompassed both the
INK4A and INK4B loci, however, our data do not permit
discrimination between the potential roles of p15, p16, and
p19 inactivation in these events.
Aberrant methylation of the p16 and p15 gene promoters
has been associated with transcriptional repression in pre-
Table 3 Chromosome 9p deletions in HT1080.6TG and hybrid-derived tumor cells
Tumor or cell line D9S162 D9S157 p16 p15 D9S171 D9S259 D9S169
HT1080.6TG 1
a 12 2 1 11
22222222222222222222
K894.12T2 ND D/U 22 U D D/U
K894.18T1 ND R 22 UR R
K894.18T2 ND R 22 UR R
K894.19T1 ND D/U 22 U D D/U
K894.19T2 ND D/U 22 U D D/U
K894.23T1 ND D/U 22 U D D/U
K893.23T2 ND D/U 22 U D D/U
22222222222222222222
a The allelic status of loci is depicted as follows: 1, alleles detected; 2, no alleles detected; R, fibroblast-derived allele(s) retained; D, no fibroblast-derived
alleles retained; U, uninformative; D/U, one fibroblast-derived allele deleted, other allele uninformative; ND, not done.
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Fig. 5. Deletion of fibroblast-derived p16 alleles in Hy397 hybrid cells
containing fibroblast-derived chromosome 9 markers. A, the p16 exon 3
region containing an MspI polymorphism was amplified from genomic
DNA of parental fibroblast and squamous cell carcinoma cell lines as well
as five Hy397 hybrid cell lines. PCR products were digested with MspI.
Note that GM01429 alleles are completely digested, whereas 388HR.4
alleles are fully resistant to digestion. B, genomic DNA from the parental
and hybrid cell lines was amplified using primers specific for the chromo-
some 9 microsatellite locus D9S273. Note that the smaller, GM01429-
specific allele is present in each of the hybrid cell lines.
Table 4 p16-induced suppression of clonogenicity in parental tumor
cell lines
Cell line
No. of transfectant colonies
(6SD) Clonogenicity
fraction
a
pCDKN2AWT pCDNA3
HT1080.6TG 224 (13) 502 (18) 0.45
A388.6TG 28 (4) 97 (5) 0.29
a No. of pCDKN2AWT clonies/no. of pCDNA3 colonies.
31 Cell Growth & Differentiationvious reports (11–16). We used the somatic cell hybrid sys-
tems to ask whether epigenetic inactivation is the functional
equivalent of genetic inactivation of tumor suppressor alleles
and, potentially, to gain insight into the determinants that
direct epigenetic versus genetic inactivation. We assessed
the status of the fibroblast-derived p16 alleles in hybrid cell
lines between human fibroblasts and 388HR.4 cells, a squa-
mous cell carcinoma cell line that has inactivated p16 by
methylation-associated epigenetic repression. The deletion
of fibroblast-derived p16 alleles and concomitant retention of
methylated 388NR.4-derived alleles observed after 20 pas-
sages in tissue culture suggests that epigenetic inactivation
and genetic deletion of the parental tumor cell p16 alleles
were functionally equivalent in these hybrid cell systems.
The molecular processes resulting in aberrant methylation-
associated transcriptional repression of p16 and p15 are not
well defined. The deletion, rather than methylation, of fibro-
blast-derived p16 alleles observed in all five Hy397 hybrid
cell lines suggests that p16 methylation in this system is
probably not attributable to a 388HR.4-derived factor capa-
ble of acting in trans to silence the p16 locus. We have shown
previously that parental cell methylation patterns were re-
tained at alleles of most CpG island loci K894 hybrid cells
(26). These data further suggest that the determinants of
aberrant p16 repression act in cis with respect to the inac-
tivated locus. Further investigation will be necessary to iden-
tify these putative cis-acting signals.
One approach to the identification of tumor suppressor
genes is to map deletions of nonneoplastic parental cell-
derived alleles in transformed somatic cell hybrids and then
to identify inactivating mutations of neoplastic parental cell-
derived alleles of candidate genes. Our results demonstrate
that deletions of nonneoplastic cell-derived chromosomes in
somatic cell hybrids can mark neoplastic cell-derived loci
inactivated by epigenetic as well as genetic mechanisms.
This observation suggests that a rigorous analysis of candi-
date suppressor loci identified in cell hybridization and, per-
haps, chromosome transfer experiments should include
methylation or chromatin structural analysis as well as mu-
tation and deletion analyses.
Materials and Methods
Cell Lines. The cell lines used in this study are listed and described in
Table 1. BBT human diploid fibroblasts were the generous gift of Dr.
Darwin J. Prockop (Thomas Jefferson Medical College, Philadelphia, PA).
GM02291 and GM01429 human fibroblasts were purchased from the
Coriell Cell Repositories (Camden, NJ). Hypoxanthine phosphoribosyl-
transferase-deficient HT1080.6TG human fibrosarcoma cells, SFTH300
and SFTH300TR1 hybrid cells, and A388.6TG squamous cell carcinoma
cells were the gift of Dr. Bernard Weissman (University of North Carolina,
Chapel Hill, NC). All cell lines were maintained in EMEM supplemented
with 10% FBS and incubated at 37°C at 5% CO2. The generation of K894
hybrid cell lines has been described (26). To generate Hy397 hybrids, we
transfected A388.6TG cells with a plasmid conferring hygromycin resist-
ance. These cells, termed 388HR.4, were then fused as described previ-
ously (26) with GM01429 fibroblasts, which carry an (Xq;9p) translocation,
and hybrids were selected in medium supplemented with hygromycin (150
mg/ml) and 13 hypoxanthine, aminopterin, and thymidine (Sigma Chem-
ical Co., St. Louis, MO). Individual clones were isolated after 3–5 weeks.
Multiplex Genomic PCR for p16 and p15. PCRs were carried out in
10 mM Tris (pH 8.6), 50 mM KCl, 100 mg/ml gelatin, 1.5 mM MgCl2, 0.2 mM
dNTPs, 0.5 mM each primer, 50 ng of genomic DNA, and 1 unit of Taq
polymerase (Life Technologies, Inc.) per 50-ml reaction. Oligonucleotide
primers for p16/c-myc PCR were: p16 (exon 2), forward, 59-CCACCCT-
GGCTCTGACCATTCTGT, and reverse, 59-59-CATCAGTCCTCACCT-
GAGCCT; and c-myc, forward, 59-AAGTGCGTCTCCGAGATAGCAGGG,
and reverse, 59-CGTCCGGGTCGCAGATGAAACTCT. Reactions were
supplemented with 4% DMSO. Cycling parameters were as follows: 94°C
for 5 min; then 35 cycles of 94°C for 40 s, 62° for 45 s, and 72° for 40 s;
and final extension at 72°C for 5 min. Coamplification of p15 and c-myc
was performed using p15 primers flanking exon 1 (forward, 59-TTTCCCA-
GAAGCAATCCAGGCGCG, and reverse, 59-CGCTCTAGGTTCCAGC-
CCCGATCC) in reactions supplemented with 4% DMSO. Cycling param-
eters were: 94°C for 5 min; then 35 cycles of 94°C for 40 s, 65°C for 35 s,
72°C for 40 s; and final extension at 72°C for 5 min. Ten ml of the reaction
products were fractionated on a 2% agarose gel. DNA was then trans-
ferred to nylon membranes and hybridized to random hexamer-labeled
probes generated from the cloned PCR fragments.
Multiplex RT-PCR for p16 and p15 mRNA Expression. Total cellular
RNA (2.5 mg; Ref. 33) was reverse-transcribed in 30-ml reactions contain-
ing 150 ng of random hexamers (Life Technologies, Inc., Gaithersburg,
MD), 0.5 mM dNTPs, 0.3 ml of RNAsin (Promega, Madison, WI), buffer, DTT
as supplied by the manufacturer (Life Technologies, Inc.), and 1.5 ml (300
units) murine Moloney leukemia virus reverse transcriptase (Life Technol-
ogies, Inc.) or water. Reactions were incubated1ha t37°C, heat-inacti-
vated for 5 min at 95°C, and then held on ice. Five ml of the RT reactions
were used as template for PCRs with p16 primers (exon 1a, forward,
59-ATGGAGCCTTCGGCTGACTGGCTG; and reverse, 59-CGAGGTTTCT-
CAGAGCCTCTCTGG) or p15 primers (forward, 59-ATGCGCGAGGAGAA-
CAAGGGCATG; and reverse, 59-AAGTCGTTGTGGGCGGCTGGGGAA)
and GAPDH primers (GAPDH, forward, 59-TCTTCTTTTGCGTCGCCAGC-
CGAG; and reverse, 59-AATGCCAGCCCCAGCGTCAAAGGA) in reactions
supplemented with 4% DMSO. Cycling parameters for both p16/GAPDH
and p15/GAPDH PCRs were: 94°C for 5 min; then 35 cycles of 94°C for
40 s, 67°C for 30 s, and 72°C for 40 s; and final extension at 72°C for 5
min. Ten ml of the reaction products were separated on agarose gels,
transferred, and hybridized as described above.
PCR Analysis of Microsatellite Markers. Oligonucleotide primers
specific for loci D9S157, D9S162, D9S169, D9S171, D9S259, and
D9S273 were purchased from Research Genetics (Huntsville, AL). PCR
amplification was performed using 25 ng of genomic DNA in 25-ml reac-
tions. Cycling parameters were as follows: 94°C for 4 min; then 30–35
cycles of 94°C for 40 s, 55°C for 30 s, 72°C for 1 min; and final extension
at 72°C for 4 min. Reaction products were separated in 3% low melting
point agarose gels and visualized by UV fluorescence after staining in
ethidium bromide. Alternatively, one oligonucleotide primer per reaction
series was end-labeled with [g-
32P]ATP and Klenow fragment. PCR prod-
ucts were then resolved on 5% acrylamide/8 M urea sequencing gels and
visualized after autoradiographic exposure of the dried gels.
p16 MspI Polymorphism Analysis. The region containing a RFLP
identified by MspIi ne x o n3o ft h ep16 gene (10) was amplified with
primers P16E3.1 (59-TAGGGACGGCAAGAGAGGAGGGC) and P16E3.2
(59-TGAAAACTACGAAAGCGGGGTGGG) in 25-ml reactions containing 25
ng of genomic DNA and 4% DMSO. Cycling parameters were 94°C for 5
min; then 35 cycles of 94°C for 40 s, 64°C for 45 s, 72°C for 30 s; and final
extension at 72°C for 5 min. PCR products (10 ml of each 25-ml reaction)
were then digested for 2 h with 10 units of MspI (New England Biolabs,
Beverly, MA) in the buffer supplied by the manufacturer in a reaction
volume of 20 ml. The digestion products were then separated on a 2%
agarose gel and visualized by UV fluorescence of the ethidium bromide-
stained gel.
Tumorigenicity Assays. Cells (2 3 10
6–5 3 10
6) were injected s.c.
into the flanks of athymic nude mice (one injection per mouse; four mice
per cell line). Individual tumors were excised and genomic DNA was
prepared by cell lysis and digestion SDS-proteinase K followed by phenol-
chloroform extraction.
Transfection Assays. Cells were grown to ;75% confluence in
100-mm tissue culture dishes. Cells were transfected with 10 mgo f
BglII-linearized DNA from the plasmids pCDNA3 (Invitrogen) or
pCDKN2AWT (the generous gift of Dr. H-J. Su Huang, Ludwig Institute for
Cancer Research, La Jolla, CA) or mock-transfected with TE buffer. Trans-
fection was performed with Lipofectamine (Life Technologies, Inc.) in
EMEM without FBS for 5 h, after which transfection medium was removed
and cells were incubated overnight in EMEM supplemented with 10%
FBS. On the following day, cell monolayers were trypsinized and equiv-
alent numbers of cells were plated in 100-mm dishes in EMEM with 10%
32 p16/p15 Deletion in Human Somatic Cell HybridsFBS containing G418 (Life Technologies, Inc.) at 300 mg/ml (A388.6TG) or
500 mg/ml (HT1080.6TG). Macroscopic colonies were counted after 10
days by staining with methylene blue.
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